NAD+ precursors: in scope for partial reprogramming, or longevity-adjacent?

Scope decision pass. Evaluates NMN, NR, NMNH, and NAD+ itself for inclusion in the partial-reprogramming evidence map — with a critical mechanistic conflict surfaced.

Computational research use only — not clinical, not therapeutic, not wet-lab instruction.

Scope verdict

Defer NAD+ precursors to a separate longevity-adjacency report — with one important exception.

The exception: NAD+/SIRT6 axis directly antagonizes the WP2.1 KAT8 program (SIRT6 is the primary mammalian H4K16 deacetylase). NAD+ precursors must therefore be cross-referenced into the WP2.1 risk model, even if they don't sit in the main reprogramming candidate table. This conflict is the most important mechanistic finding of WP1.3.

1. The headline conflict: NAD+/SIRT6 vs. KAT8/H4K16ac

Mechanistic conflict (critical)

NAD+ precursors (NMN, NR) raise intracellular NAD+, which activates sirtuins. SIRT6 is the primary mammalian H4K16 deacetylase — meaning NAD+ supplementation drives down H4K16ac at chromatin. This is the exact opposite direction of the WP2.1 KAT8-activator program, which seeks to raise H4K16ac.

Implication: a partial-reprogramming program that combines NAD+ precursor priming with KAT8 activation is mechanistically self-defeating. The two interventions cancel at the H4K16ac mark.

This isn't a reason to dismiss NAD+ from the longevity field — SIRT6 itself extends mouse lifespan (Kanfi 2012), so the H4K16ac-lowering effect is offset by other SIRT6 benefits at the organismal level. But for the specific goal of partial reprogramming via H4K16ac restoration, NAD+ supplementation is at best neutral and may be net-negative.

Kanfi Y et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483:218. PMID: 22367546.

Michishita E et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature. 2008;452:492. PMID: 18337721. (SIRT6 deacetylase activity context.)

2. NAD+ precursor mechanism scoring (against partial-reprogramming endpoints, not longevity)

Compound	Pathway entry	EV	MR (reprog)	SP	TF	WS	Composite	Note
NMN (nicotinamide mononucleotide)	Direct NAD+ precursor → SIRT activation	7	3	8	9	3	6.0	Raises NAD+; SIRT6 activation antagonizes H4K16ac. Longevity literature ample; partial-reprogramming evidence thin.
NR (nicotinamide riboside)	NRK kinase → NMN → NAD+	8	3	9	9	3	6.4	Same mechanism as NMN; better human PK data; same SIRT6/H4K16ac antagonism.
NMNH (reduced NMN)	Bypass NAMPT, raises NAD+ via reduced pathway	4	3	6	5	7	5.0	Newer entrant; less PK data; same downstream antagonism issue.
Nicotinamide (NAM) high-dose	NAD+ precursor + sirtuin product-inhibitor	7	5	7	9	5	6.6	Inverts the conflict: high-dose NAM inhibits sirtuins (product inhibition), so could in principle raise H4K16ac. Mechanistically interesting but pharmacologically messy at high doses.

Mechanistic Relevance scored against partial-reprogramming endpoints specifically, not against general longevity. NAD+ precursors all score moderately on aging-clock readouts (longevity context) but low on direct reprogramming biology.

3. What the reprogramming literature actually says about NAD+

EVIDENCE (limited)

iPSC reprogramming requires a metabolic switch from oxidative phosphorylation to glycolysis (Folmes et al. 2011). NAD+ levels and the NAD+/NADH ratio shift substantially during reprogramming. Direct evidence that NAD+ precursor supplementation enhances reprogramming efficiency is limited and contested — some studies report enhancement, others report inhibition or no effect, depending on cell system and dosing.

HYPOTHESIS

NAD+'s primary therapeutic narrative (mitochondrial function, sirtuin activation, energy metabolism) is genuinely compelling for healthspan but operates on a different mechanistic axis than partial reprogramming (epigenetic mark restoration). Treating NAD+ as a "longevity intervention" is more defensible than treating it as a "reprogramming intervention."

Folmes CD et al. Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab. 2011;14:264. PMID: 21803296.

Yoshino J et al. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27:513. PMID: 29249689.

4. Scope decision and downstream effects

4A. NAD+ precursors are OUT of the main partial-reprogramming candidate table

The mechanism is healthspan/sirtuin-axis, not partial-reprogramming epigenetics.
The NAD+/SIRT6/H4K16ac antagonism with the WP2.1 KAT8 program would muddy the central narrative.
Including them would be the kind of "category creep" that erodes RIA-01's evidence/hypothesis lane discipline.

4B. NAD+ precursors ARE flagged as a Risk in WP2.1

If a future Atlas Bio program combines KAT8 activation with patient lifestyle / co-prescribed NAD+ supplements, the H4K16ac restoration effect could be partially neutralized.
WP2.1 should add a "co-administration risk" line for NAD+ precursors in the safety/risk section.

4C. The Nicotinamide-as-sirtuin-inhibitor inversion is filed as a future hypothesis

High-dose NAM inhibits sirtuins (product inhibition) and could theoretically raise H4K16ac. Mechanistically interesting; pharmacologically messy at the doses required. Worth a single-line entry in the WP2.1 risk model under "co-administration considerations" rather than a candidate of its own.

4D. A separate "Longevity Adjacency" report is recommended

NAD+ precursors, rapamycin, metformin, senolytics, and similar geroscience interventions deserve their own RIA-01 sub-study with longevity (not reprogramming) endpoints.
Atlas Bio's parent Longevity Program (LON-LEAD / LON-S1..S6, Apr 2026) is the natural home for that adjacency report; recommend RIA-01 collaborate rather than duplicate.

5. Cross-references and propagation to other deliverables

Deliverable	Required update
WP1 Evidence Map (v0.2)	Add a footnote in section 8 (Limitations) confirming WP1.3 scope decision: NAD+ precursors deferred. Updated in next pass.
WP2.1 KAT8 Activator Deep-Dive	Add NAD+/SIRT6 antagonism to the safety / co-administration considerations of Strategy 1 and Strategy 3 cards.
Longevity Program (LON-LEAD)	Flag the cross-walk: RIA-01's KAT8 program and LON's NAD+/sirtuin work overlap on H4K16ac in opposite directions. Worth a coordination memo to avoid contradictory narrative.
Future Atlas Bio investor deck	If KAT8 program advances, the deck should explicitly address — not avoid — the NAD+ supplement question patients/investors will ask.